Market: NASD |
Currency: USD
Address: 118 Avenue , 14315
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
📈 Aurinia Pharmaceuticals Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$11.71
-
Upside/Downside from Analyst Target:
-3.03%
-
Broker Call:
11
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
100-200%
-
Net Income Growth Range (1Y):
100-200%
-
Revenue Growth Range (1Y):
25-50%
-
Upcoming Earnings Date:
2025-11-06
-
EPS Estimate:
0.16
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Aurinia Pharmaceuticals Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-07-31 | 0.16 |
| 2025-05-12 | 0.16 |
| 2025-02-27 | 0.01 |
| 2024-11-07 | 0.1 |
| 2024-08-01 | 0.01 |
| 2024-05-02 | -0.07 |
| 2024-02-15 | -0.19 |
| 2023-11-02 | -0.09 |
| 2023-08-03 | -0.08 |
| 2023-05-04 | -0.18 |
| 2023-02-28 | -0.18 |
| 2022-11-03 | -0.06 |
| 2022-08-04 | -0.25 |
| 2022-05-10 | -0.27 |
| 2022-02-28 | -0.25 |
| 2021-11-03 | -0.39 |
| 2021-08-05 | -0.37 |
| 2021-05-06 | -0.4 |
| 2021-02-24 | -0.05 |
| 2020-11-10 | -0.3 |
| 2020-08-11 | -0.26 |
| 2020-05-14 | -0.23 |
| 2020-03-05 | -0.29 |
| 2019-11-14 | -0.21 |
📰 Related News & Research
No related articles found for "aurinia pharmaceuticals".
